07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Agendia sales and marketing update

Agendia launched its colon cancer recurrence test ColoPrint for stage II colon cancer prognosis and prediction. ColoPrint is a microarray-based 18-gene expression profile. Agendia B.V. , Amsterdam, the Netherlands   Business: Diagnostic  ...
07:00 , Jun 4, 2012 |  BioCentury  |  Finance

Agendia's private party

Agendia's private party Dutch molecular diagnostics play Agendia B.V. expects to use this year's largest European venture capital round to reach breakeven. The company raised $65 million last week in an equity financing led by...
01:08 , Jun 1, 2012 |  BC Extra  |  Financial News

Agendia raises $65 million

Agendia B.V. (Amsterdam, the Netherlands) raised $65 million in a financing led by Debiopharm Group . All existing investors participated, including Gilde Healthcare Partners; Van Herk Group; ING Corporate Investments; and Breedinvest, as well as...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Company News

Agendia B.V., The Netherlands Cancer Institute, University of Texas deal

Agendia partnered with the university's M.D. Anderson Cancer Center and Netherlands Cancer Institute to integrate genomic and proteomic technologies, and pathological and clinical data to improve diagnosis and treatment options for colorectal cancer. The collaboration...
07:00 , Jun 13, 2011 |  BioCentury  |  Finance

Agendia's agenda

Molecular diagnostics play Agendia B.V. expects to start trading on June 21 on NYSE Euronext in Amsterdam. It hopes to raise up to €75 million ($109.6 million) through the sale of up to 4.6 million...
07:00 , May 23, 2011 |  BioCentury  |  Finance

Euro IPOs

Euro IPOs French cancer diagnostic play Median Technologies Inc. and Swedish dermatology company Moberg Derma AB completed IPOs last week, while Dutch molecular diagnostic company Agendia B.V. added itself to the queue. Median raised €10...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Clinical News

ColoPrint diagnostic data

Researchers from Technische Universitat Munchen showed that in tumor tissue samples from 137 patients who underwent curative resection for stage II colorectal cancer, ColoPrint was the only parameter to significantly predict the development of distant...
07:00 , Jun 8, 2009 |  BC Week In Review  |  Clinical News

ColoPrint: Pilot trial data

In tumor tissue samples from 180 patients with stage I, II and III colorectal cancer undergoing surgery, ColoPrint classified 61% of the samples as low-risk of recurrence and 39% as high-risk. The 5-year distant metastasis...